The clinical performance is complex and often involves multiple systems. Early identification and standardization of the diagnosis are essential for improving the prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in connecting teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment programs. Treatment and management of H. P.
involves the development of multiple stages of treatment, typically including drug therapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HLHP. The platform serves the China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, to provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.